Researchers led by biomedical engineering Professor Shy Shoham of the Technion-Israel Institute of Technology are testing the power of holography to artificially stimulate cells in the eye, with hopes of developing a new strategy for bionic vision restoration.
Cogmedix, a subsidiary of Coghlin Companies, Inc. has recently expanded their medical device contract manufacturing facility to add an additional 8,500 square feet. The increase in space is accommodating growth in medical device manufacturing, servicing, warehousing, and order fulfillment.
A new study by Columbia Engineering researchers finds that the infant brain does not control its blood flow in the same way as the adult brain. The paper, which the scientists say could change the way researchers study brain development in infants and children, is published in the February 18 Early Online edition of Proceedings of the National Academy of Sciences (PNAS).
Reportlinker.com announces that a new market research report is available in its catalogue: Intraocular Lens (IOL): Market Shares, Strategies, and Forecasts, Worldwide, Nanotechnology, 2013 to 2018
A new study from engineers at Rensselaer Polytechnic Institute and the University of California, Berkeley, pairs light and genetics to give researchers a powerful new tool for manipulating cells. Results of the study, published in the journal Nature Methods, show how blue light can be used as a switch to prompt targeted proteins to accumulate into large clusters.
Researchers from the Institute of Photonic Sciences (ICFO), in collaboration with the CSIC and Macquarie University in Australia, have developed a new technique, similar to the MRI but with a much higher resolution and sensitivity, which has the ability to scan individual cells. In an article published in Nature Nanotech, and highlighted by Nature, ICFO Prof. Romain Quidant explains how this was accomplished using artificial atoms, diamond nanoparticles doped with nitrogen impurity, to probe very weak magnetic fields such as those generated in some biological molecules.
Two engineers of the Cooperation & Development Center and a physician, medical director of the EssentialMed Foundation, launch a project to develop an appropriate diagnostic imaging system adapted to the context of developing countries.
Monitoring the hepatic function of unresectable liver cancer patients, measured by 99mTc-labeled iminodiacetic acid (HIDA) via single-photon emission computed tomography (SPECT) prior to and during radiation therapy, provides vital information that could guide more customized treatment plans and reduce risks of liver injury, according to research being presented at the 2013 Cancer Imaging and Radiation Therapy Symposium.
Verisante Technology, Inc. (the "Company" or "Verisante"), a leader in cancer detection technology, announced today that the Company has won a 2013 Prism Award in the Life Sciences and Biophotonics category for Aura™, a revolutionary skin cancer detection device. The winners were announced at an Awards banquet on February 6, 2013 in San Francisco.
BIOLASE, Inc., the world's leading manufacturer and distributor of dental lasers, announced today that the U.S. Food and Drug Administration (FDA) has cleared the 940nm Diolase 10 diode soft tissue laser for use in 19 additional medical markets including: ear, nose and throat, oral surgery, arthroscopy, gastroenterology, general surgery, dermatology, plastic surgery, podiatry, GI/GU, gynecology, neurosurgery, ophthalmology, pulmonary surgery, cardiac surgery, thoracic surgery, urology, dermatology, aesthetics, and vascular surgery. This FDA clearance includes over 80 different procedures.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.